Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000006711 | SCV000800568 | uncertain significance | Citrullinemia type I | 2017-08-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002512848 | SCV003441392 | likely pathogenic | Citrullinemia | 2022-02-20 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Lys310 amino acid residue in ASS1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 12815590, 15863597; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 6339). This missense change has been observed in individual(s) with citrullinemia type I (PMID: 12815590, 15266621). This variant is present in population databases (rs121908648, gnomAD 0.002%). This sequence change replaces lysine, which is basic and polar, with glutamine, which is neutral and polar, at codon 310 of the ASS1 protein (p.Lys310Gln). |
OMIM | RCV000006711 | SCV000026902 | pathogenic | Citrullinemia type I | 2004-08-15 | no assertion criteria provided | literature only |